SCHEMBL1285448

SCHEMBL1285448

CC(Cc1ccc2ccccc2c1)C(N)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.62
HTR2C P28335 1/20 0.62
HTR2B P41595 1/20 0.62
EPHX1 P07099 2/20 0.51
MMP9 P14780 3/20 0.48
FCER2 P06734 2/20 0.48
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
CYP1A2 P05177 2/20 0.47
CYP2A6 P11509 1/20 0.47
MME P08473 1/20 0.47
ACE P12821 1/20 0.47
CPA1 P15085 1/20 0.47
ACE2 Q9BYF1 1/20 0.47
MC5R P33032 3/20 0.46
MC1R Q01726 2/20 0.46
MC4R P32245 1/20 0.46
MMP8 P22894 2/20 0.46
F2 P00734 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209550 1.00 HTR2A (0.62) HTR2AHTR2CHTR2BEPHX1MMP9
SCHEMBL27941074 0.95 HTR2A (0.56) HTR2AHTR2CHTR2BEPHX1MMP9
SCHEMBL31036986 0.88 PPARG (0.50) HTR2AHTR2CHTR2BEPHX1PPARG
SCHEMBL14945003 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9PPARG
SCHEMBL16743957 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9CYP1A2
SCHEMBL13126117 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9CYP1A2
SCHEMBL12191624 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9PPARG
SCHEMBL14032460 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9PPARG
SCHEMBL17679171 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9PPARG
SCHEMBL26178695 0.85 HTR2A (0.59) HTR2AHTR2CHTR2BMMP9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110194731-B Mercaptopropionic acid amide compound, preparation method and medicinal application thereof 复旦大学 2021-05-04 CN disclosed
US-20180305373-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2018-10-25 US disclosed
US-10017522-B2 Alpha helix mimetics and methods relating thereto Prism BioLab Co., Ltd. (JP) 2018-07-10 US disclosed
US-9682996-B2 Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Prism BioLab Co., Ltd. (JP) 2017-06-20 US disclosed
US-20150376204-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS Prism BioLab Co., Ltd. (JP) 2015-12-31 US disclosed
US-20150368262-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2015-12-24 US disclosed
US-9126981-B2 Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Prism BioLab Co., Ltd. (JP) 2015-09-08 US disclosed
US-9040531-B2 Alpha helix mimetics and methods relating thereto Prism BioLab Co., Ltd. (JP) 2015-05-26 US disclosed
US-8809280-B2 Therapeutic peptides LYTIX BIOPHARMA AS (NO) 2014-08-19 US disclosed
US-20140221657-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS PRISM BIOLAB CORPORATION (JP) 2014-08-07 US disclosed
US-20130035296-A1 THERAPEUTIC PEPTIDES LYTIX BIOPHARMA AS (NO) 2013-02-07 US disclosed
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2012-04-12 US disclosed
EP-1556361-A2 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2005-07-27 EP disclosed
WO-2004037797-A2 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY THE PROCTER & GAMBLE COMPANY (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368262-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO HTR2A 3026/4885HTR2C 3558/4885HTR2B 2710/4885
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO HTR2A 3026/4885HTR2C 3558/4885HTR2B 2710/4885
US-20130035296-A1 THERAPEUTIC PEPTIDES VIP, LNPEP, ANPEP HTR2A 4186/4885HTR2C 4581/4885HTR2B 3395/4885
US-20180305373-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO HTR2A 3026/4885HTR2C 3558/4885HTR2B 2710/4885
US-10017522-B2 Alpha helix mimetics and methods relating thereto PLOD3, COL1A1, THPO HTR2A 3026/4885HTR2C 3558/4885HTR2B 2710/4885
US-20150376204-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS CREBBP, CTNNB1, CTNNA1 HTR2A 3333/4885HTR2C 4046/4885HTR2B 3696/4885
US-20140221657-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS CREBBP, CTNNB1, CTNNA1 HTR2A 3333/4885HTR2C 4046/4885HTR2B 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.